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ABSTRACT
Epithelial tumors of the lacrimal gland are rare and usually develop in the orbital lobe. We report the 
exceedingly rare occurrence of a primary adenoid cystic carcinoma in the palpebral lobe of the 
lacrimal gland. A 26-year-old female was referred for evaluation of a gradually enlarging mass in the 
lateral upper eyelid, previously diagnosed as a chalazion. Computed tomography revealed 
a heterogeneous round lesion anterior to the orbital rim. Excisional biopsy was compatible with 
an adenoid cystic carcinoma. After excluding distant metastasis, and as the patient refused adjuvant 
radiotherapy, a second surgical procedure, with wide local excision, was indicated. Follow-up 
showed no recurrence. This case highlights the importance of performing a thorough clinical 
examination when diagnosing any lateral upper eyelid mass. A high index of suspicion for malig-
nant tumors of the lacrimal gland should always be maintained, and a complete excision with 
histological analysis should be preferred whenever possible.
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Introduction
Lacrimal gland (LG) tumors are rare, corresponding to 
3–18% of all orbital lesions.1 Primary epithelial tumors 
account for 20–45% of all neoplasms of the LG, half of 
which are malignant.1,2 In this latter subgroup, adenoid 
cystic carcinoma (ACC) accounts for approximately 60% 
of cases2 and generally arises from the orbital lobe. ACC 
of the LG presents a bimodal age distribution, occurring 
most often in middle age, with a second peak in the first 
decade of life.2 Usually, patients describe the progression 
of symptoms over less than one year, often less than six 
months.3 Primary malignant epithelial tumors originating 
from the palpebral lobe of the LG are exceedingly rare, 
with only three cases described in the literature.4 Among 
these, only one corresponded to an ACC.4
We report a case of ACC arising in the palpebral lobe 
of the LG in a 26-year-old female patient, initially mis-
diagnosed as a chalazion, emphasizing the importance of 
a careful preoperative examination of all eyelid lesions.
Case report
A 26-year-old black female was referred for evaluation of 
a right upper eyelid mass with progressive growth in the 
last eight months. A previous surgical excision had been 
attempted six months earlier, with no improvement.
The patient denied pain, paresthesia, diplopia or 
other associated ophthalmological symptoms. On clin-
ical examination, a painless, non-tender, mobile mass 
of 1 to 1.5-cm was palpated laterally on the upper eyelid 
(Figure 1A). A prolapsed palpebral lobe of the LG was 
visible after eyelid eversion, with no identifiable mass. 
Visual acuity was 20/20 on both eyes, ocular motility 
was normal, and no proptosis or globe displacement 
was observed. Computerized tomography showed 
a round well-circumscribed heterogeneous lesion, 
anterior to the orbital rim, with no associated bone 
erosion or globe deformation (Figure 1B). An exci-
sional biopsy was performed through an upper eyelid 
skin-crease approach. An exceedingly thin levator apo-
neurosis was incised, and an encapsulated mass 
removed with the capsule intact. Histopathological 
examination revealed a 16 ! 10 x 8 mm low-grade 
ACC with a cribriform pattern and no vascular or 
perineural spread (Figure 2A–C). Radiological staging 
excluded distant metastases, and orbital and brain 
magnetic resonance images did not show any signs of 
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perineural spread or suspicious soft tissue changes. 
After a multidisciplinary tumor board, adjuvant radio-
therapy was indicated; however, it was refused as the 
patient needed to return to her native country 
(Angola). As an alternative, a second surgical proce-
dure for wide local excision followed by close surveil-
lance was planned. Two weeks after the first surgery, 
the remaining palpebral lobe of the lacrimal gland was 
removed along with adjacent tissues. No residual 
tumor was detected. The patient has been followed up 
regularly with clinical examination and magnetic reso-
nance imaging, and three years after the second proce-
dure, no signs of recurrence were noticed (Figure 3). In 
the last evaluation, visual acuity, intraocular pressures, 
globe position, and motility were unremarkable, and 
only a 1 mm right ptosis and mild dry eye symptoms, 
consistent with a Schirmer test (without anesthetic) of 
4 mm on the right and 16 mm on the left, were 
observed. Regular lubrication has been recommended 
for the control of dry eye symptoms.
Discussion
The LG is composed of two portions: an orbital (deep) 
and a palpebral (superficial) lobe, separated by the lat-
eral horn of the levator muscle aponeurosis.5 The pre-
sence of cells of di"erent histological origins allows the 
development of several distinct types of neoplasms, 
usually divided into epithelial, lymphoid and 
mesenchymal.6 To the best of our knowledge, only 75 
primary tumors of the palpebral lobe were reported in 
the literature4,7–20 (Supplementary Table 1). Among 
these, 71 had an epithelial origin, in most cases (95.8%) 
pleomorphic adenomas (PA),4,7–20 the remaining corre-
sponding to one carcinoma in-pleomorphic adenoma, 
one carcinoma ex-pleomorphic adenoma, and only one 
case was compatible with an ACC.4
In 1996, Vangveeravong S. et al. reported the clinical 
features and treatment outcomes of six tumors of the 
palpebral lobe of the LG comprising three benign and 
three malignant lesions, including one ACC.4 All tumors 
were initially described as a progressively growing palp-
able mass or swelling in the lateral upper eyelid, with no 
other signs such as proptosis, globe displacement, motility 
or visual impairment. These nonspecific clinical features 
include a wide range of di"erential diagnoses, such as 
chalazion, dermoid or sebaceous cysts, as well as epithelial 
and non-epithelial lesions of the lacrimal gland, including 
dacryops, dacryoadenitis or lymphoma. In addition, ecto-
pic lacrimal gland tissue may present in the upper or 
lower eyelid as masses,21 where benign and malignant 
lesions can develop. In our patient, although the lesion 
could be similar in shape and topography to a chalazion, 
careful palpation allowed its location outside the tarsal 
Figure 1. Initial presentation. (A) Well-defined 10 x 15-mm mobile mass in the temporal area of the right upper eyelid. (B) Orbital 
computed tomography showing a round heterogeneous soft tissue lesion in the superotemporal quadrant of the right orbit.
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plate. Intraoperatively, an origin from the palpebral lobe 
was assumed given its position immediately below a thin 
and locally atrophic levator aponeurosis.
We agree that any palpable and well-circumscribed 
lesion with an anterior location outside the orbital rim, 
confirmed by imaging, should be initially managed with 
complete excision. Firstly, because when located in the 
superotemporal region of the upper eyelid, there is a not 
negligible probability of corresponding to a PA, with 
a significant risk of recurrence (and possible malignant 
transformation) if incompletely extirpated22–24; and sec-
ondly, also highlighted by Vangveeravong et al., there is 
no reason to perform a partial resection, or even inci-
sional biopsy, of a mass that can be easily excised.4
We can find some similarities between our patient 
and the 41-year-old male described by Vangveeravong 
et al.4, and the most commonly described presentation 
of orbital lobe ACC: both presented less than one year of 
symptom progression and followed the classic bimodal 
age distribution. The distinguishing features were the 
absence of pain, paresthesia or bone changes, which 
are more suggestive of malignancy yet also inconsis-
tently present in orbital lobe tumors.25 The more ante-
rior location of these palpebral lobe lesions, with no 
contact with the orbital rim, may also justify the absence 
of earlier bone changes. Two cases of palpebral lobe 
ACC are, however, insu#cient to draw any conclusions 
about its specific behavior in this anatomic area. We 
believe that there might be an under-reporting of lesions 
primarily arising from the palpebral lobe. Most of the 
case series found in our literature review lack the speci-
fication of which lobe the tumors originated from, cate-
gorizing them according to size and/or stage (American 
Joint Committee on Cancer staging system). We can 
point out three possible explanations for this: 1) 
Considering that most of these studies are retrospective, 
the authors may use the generic term of LG tumor as this 
is the description shown in clinical files, pathology and 
imaging reports; 2) The authors do not value such dis-
tinction assuming that it does not interfere with the 
management or prognosis; 3) Malignant tumors arising 
from the palpebral lobe are in fact, exceedingly rare. We 
Figure 2. (A) Histopathology, H&E 100x, of the eyelid lesion showing an epithelial neoplasm with a cribriform pattern. In immuno-
histochemistry, Kit (CD117) typically marks epithelial (inner) cells (B) and p63 marks myoepithelial (peripheral) cells (C).
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found only one retrospective study by Shields JA et al. 
specifying whether unilateral lacrimal gland lesions 
showed an involvement of the palpebral and/or the 
orbital lobe on magnetic resonance imaging.26 In their 
series, only chronic dacryoadenitis showed a palpebral 
lobe extension. Therefore, we highlight the need to pre-
sent this distinction whenever possible, so that di"er-
ences in the behavior and the impact of treatments now 
used in orbital lobe tumors might be evaluated. Few 
other cases of non-epithelial tumors originating from 
the palpebral lobe were identified (Supplementary 
Table 1) and included a neurofibroma in a 62-year-old 
man,27 a metastatic renal cell carcinoma in a 59-year-old 
man,28 an 18-month-old child with a sialoblastoma-like 
tumor with a sarcomatoid myoepithelial component,29 
and a 22-year-old woman with an epithelioid 
hemangioendothelioma.30 All these reports highlight 
the unusual occurrence of each type of lesion in this 
anatomic location and become arguments of how a high 
index of suspicion is needed for any mass in this area.
The aggressiveness and high mortality rates of lacri-
mal gland ACC are well known. Although there have 
been some controversies, the paradigm of treatment of 
this aggressive tumor has shifted over the past decades. 
Contemporary approaches now favor an eye-sparing 
multidisciplinary management whenever possible, com-
plemented with adjuvant treatment (radiotherapy and 
eventually chemotherapy).31–35 The development of new 
radiotherapy modalities such as intensity-modulated 
radiotherapy and the intensity-modulated proton ther-
apy, with fewer side e"ects, have markedly reduced the 
post-treatment burden of previous radiation delivery 
techniques.32,35,36 Neoadjuvant intra-arterial che-
motherapy has also been used with promising results,37 
and recent search for cancer-associated mutations and 
potential molecular targets has added important steps in 
the long and challenging journey of treating advanced 
forms and metastatic disease.38,39
Regarding our patient, the preference for a wide 
surgical excision as an alternative to adjuvant radio-
therapy was made considering the patient’s desire to 
return to her native country. In fact, despite all the 
advances in ACC therapy, extensive local resection 
without further treatments has been an accepted pro-
cedure in specific circumscribed lesions.3,40 That indi-
cation was considered beneficial in this particular case. 
All the prognostic factors for local recurrence and 
survival were considered, namely the lesion size 
(T1N0M0 according to the American Joint 
Committee on Cancer classification, 8th edition), the 
histologic type (non-basaloid) and the absence of peri-
neural invasion.25,32,40 Importantly, the decision also 
depended on the patient’s commitment to maintaining 
a strict clinical and radiologic surveillance.
Figure 3. (A) Clinical appearance three years after surgery shows only a mild right upper eyelid ptosis. (B) Axial MRI T1 discloses 
a discrete signal reinforcement in the external contour of the surgical area.
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In summary, we report the exceedingly rare occur-
rence of an ACC of the palpebral lobe of the LG, illustrat-
ing the importance of maintaining a high level of 
suspicion for any temporally located upper eyelid mass. 
A thorough ophthalmic examination with palpation and 
eyelid eversion is crucial and may allow the immediate 
diagnosis of benign and more common conditions such 
as dermoid/epidermoid cysts, chalazion or dacryops. Well 
delimited lesions should be removed with an en bloc 
resection technique whenever possible, with histology, 
clinical and radiological staging guiding the treatment 
plan. Also, some attention should be paid in future stu-
dies regarding the specific location of a LG tumor. More 
substantiated data may open a new paradigm in the 
management of lesions arising from the palpebral lobe.
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